血清缓激肽与前列腺癌的相关性研究  

Association of serum bradykinin and prostate cancer

作　　者：周颖[1] 吕梦琴[1] 魏睿[1] 奚玲[1] 李飞[1] Zhou Ying Lv Mengqin Wei Rui et al(Tumor Biological Research Center, Tongji Hospital, Affiliated to Tongji Medical College Huazhong University of Science and Technology, Wuhan 430030, Chin)

机构地区：[1]华中科技大学同济医学院附属同济医院肿瘤生物医学中心,湖北武汉430030

出　　处：《实用肿瘤杂志》2017年第3期212-215,共4页Journal of Practical Oncology

基　　金：国家自然科学基金面上项目(81472444)

摘　　要：目的探讨血清缓激肽在前列腺癌的诊断及鉴别诊断中的临床应用价值。方法收集68例前列腺癌患者和32例前列腺增生患者,以同期体检的健康男性32例为对照组,收集其血清,酶联免疫吸附试验(enzymelinked immuno sorbent assay,ELISA)法检测血清中的缓激肽水平,比较各组血清缓激肽水平的差异以及前列腺癌患者在不同年龄、临床分期、病理分期(Gleason评分)、前列腺特异抗原(prostate specific antigen,PSA)水平、肿瘤体积以及骨转移、淋巴结转移、局部侵犯与否状态下血清缓激肽水平的差异。比较血清缓激肽与PSA联合诊断前列腺癌和PSA独立诊断前列腺癌的敏感度差异。结果前列腺癌组血清缓激肽水平[(16.44±0.91)μg/L]低于对照组[(19.72±1.10)μg/L]和前列腺增生组[(20.93±1.80)μg/L],差异均具有统计学意义(均P<0.05)。在肿瘤体积较大的前列腺癌患者血清缓激肽水平较低(P<0.05),而血清缓激肽水平在年龄、肿瘤临床分期、病理分期(Gleason评分)、PSA水平及骨转移、淋巴结转移、局部侵犯与否方面比较差异均无统计学意义(均P>0.05)。血清缓激肽与PSA联合诊断前列腺癌较单独诊断敏感度提高(P<0.05)。结论前列腺癌患者血清缓激肽表达水平较低,且与肿瘤体积相关。血清缓激肽与PSA联合诊断前列腺癌敏感度较单独诊断高。Objective To investigate the clinical application of serum bradykinin in the diagnosis and differential di- agnosis of prostate cancer. Methods Sixty-eight cases of prostate cancer and 32 cases of benign prostate hyperplasia （BPH） were enrolled, together with 32 healthy male subjects. Serum samples were collected, and the bradykinin level was detected by enzyme-linked immunesorbent assay （ELISA）. The serum levels of bradykinin were compared for each group of patients, and were also compared in prostate cancer patients of different age, ciiniea｜ stage, pathological stage （ Gleason score） , prostate specific antigen （PSA） levels, tumor volume, bone metastases status, lymph node metastases status and local invasion level. The sensitivities of prostate cancer diagnosis were compared between bradykinin and PSA combined method and PSA alone. Results The serum bradykiuin level was lower in the prostate cancer group I （ 16. 44 ± 0.91 ） μg/L]than the control group [ （ 19.72 ±1.10） μg/L] and the BPH group [ （20.93 ±1.80） μg/L,P 〈0.05]. The serum brady- kinin level was lower in prostate cancer patients with greater tumor volume （ P 〈 0.05）, but not significantly associated with age, clinical stage, pathological stage （Gleason score）, PSA levels, bone metastasis, lymph node metastasis, or local in- vasion （P 〉 0.05）. Serum bradykinin combined with PSA improved the diagnostic sensitivity of prostate cancer compared with PSA alone （P 〈 0.05 ）. Conclusion Prostate cancer patients have lower serum bradykinin level, which is related with tumor volume. Combination of serum bradykinin and PSA increased the diagnostic sensitivity for prostate cancer com- pared with the PSA alone method.

关 键 词：前列腺肿瘤/诊断 前列腺肿瘤/免疫学 缓激肽/血液 酶联免疫吸附测定 肿瘤标记 生物学 

分 类 号：R737.25[医药卫生—肿瘤] R730.4[医药卫生—临床医学]